MedTrace Logo

Bleeding Events After Triple Antithrombotic Therapy Initiation.

NCT03203980 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2017-07-11

No results posted yet for this study

Summary

The optimal antithrombotic therapy for patients requiring anticoagulation after coronary stenting is unknown. Double platelets suppressive agents combined with oral anticoagulation (triple antithrombotic therapy) remains the Gold standard.

Our study aims at studying bleeding events occurring until 6 months after the initiation of triple antithrombotic therapy.

Conditions

Interventions

OTHER

Triple antithrombotic therapy

patients who are prescribed double antiplatelets agents and oral anticoagulation (except VKA)

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-15
Primary Completion
2018-01-15
Completion
2018-07-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03203980 on ClinicalTrials.gov